March 15, 2010 — The US Food and Drug Administration (FDA) has approved a twice-yearly 22.5-mg formulation of triptorelin pamoate injection (Trelstar, Watson Pharmaceuticals, Inc) for the palliative ...
Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Premenopausal women with ...
Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment. Background: Medical castration using gonadotropin-releasing hormone (GnRH) ...
Details concerning the Triptorelin Pamoate for Injectable Suspension medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ...
Debiopharm International SA (Debiopharm - http://www.debiopharm.com), a Swiss-based company, part of Debiopharm Group ™, today announced that triptorelin 6-month ...
Triptodur, a gonadotropin-releasing hormone (GnRH) agonist, is given as an intramuscular (IM) injection every 6 months. Arbor and Debiopharm announced the launch of Triptodur (triptorelin ...
LAUSANNE, Switzerland--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results